Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial.

"Declarations Conflicts of interestAR reports receiving grants and consulting fees from Merck and bioMerieux. Other authors declare that they have no conflicts of interest involving the work under consideration for publication. No compensation was received for this study. AT has conflicts of interest with BioMerieux, Pfizer, and MSD (advisory boards or lectures). Access to data and data analysisAR had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. FF conducted and was responsible for data analysis. Data sharingSee electronic supplementary material 6. Data and Safety Monitoring BoardFilipe Froes (Hospital Pulido Valente, Portugal), Marylaure Gavard (Grenoble University Hospital, France), Bruno Giraudeau (University of Tours, France), Marc Leone (AP/HM, France) and Pedro Póvoa (São Francisco Xavier Hospital, Portugal). Conflicts of interest AR reports receiving grants and consulting fees from Merck and bioMerieux. Other authors declare that they have no conflicts of interest involving the work under consideration for publication. No compensation was received for this study. AT has conflicts of interest with BioMerieux, Pfizer, and MSD (advisory boards or lectures)."

"Funding Supported by a grant from the European Union’s Horizon 2020 research and innovation program under grant agreement No 847782. The funding organization had no role in designing and conducting the study; collecting, managing, analyzing, and interpreting the data; preparing, reviewing, or approving the manuscript; and deciding to submit the manuscript for publication."

"The Ethics Committee of Ouest II Angers (France) approved the study protocol in March 2021. This trial complied with the Declaration of Helsinki and was registered in March 2021 (number ClinicalTrial.gov NCT04793568). The patient's legal surrogate provided written informed consent for participation. In agreement with the local laws, patients could be enrolled before the provision of legal surrogate consent if the next of kin could not be informed within the maximum delay for inclusion. When able to provide it, patient’s follow-up consent was requested up to 90 days after inclusion."